麻豆精选

• Fellow of the Royal College of Physicians, 2019
• PhD, 2010
• Member of the Royal College of Physicians (MRCP), UK, 2003
• MBChB, University 麻豆精选, 2000

Professor Sinclair graduated from the University 麻豆精选's Medical School in 2000 with honours and attained her MRCP in 2003. She completed her PhD in 2010, funded by a . Subsequently, she worked as a  Clinical Lecturer in Neurology and then a NIHR funded Clinician Scientist & Neurology Consultant.

She leads a translational research group, which seeks to establish and exploit the pathophysiological mechanisms underpinning the debilitating effects of metabolism and intracranial pressure on headache, traumatic brain injury and Idiopathic Intracranial Hypertension (IIH). She looks to develop therapeutic strategies and generate real impact while improving patient care. The translational portfolio also encompasses a clinical trials programme enabling forward (novel therapeutic molecules are under assessment in patients) and back translation (biomarker evaluation in the laboratory setting).

Professor Sinclair is the vice chair for the , the UK headache society. She has been a board member of the  and   , was on the scientific committee for the  and  was the Deputy Chair for the . She was on the research committee for the  and was also the previous patron of the patient charity .. Professor Sinclair is on the  and the , as well as the .

Professor Sinclair and her research group hosted a high profile visit from NASA, in 2019. NASA are interested in Professor Sinclair's expertise on raised intracranial pressure stemming from her leading  at University Hospitals Birmingham NHS Foundation Trust coupled with her translational science portfolio at the University 麻豆精选. Her recent discovery of the novel use of glucogon-like peptide 1 receptor agonists to reduce intracranial pressure are of particular interest to the NASA team in their quest to reduce brain pressure during long duration space travel and allow them to go beyond the moon. The NASA visitors were: , Chief Health and Medical Officer, Dr Terrance Taddeo, Johnson Space Centre Chief Medical Officer,  Dr Victor Schneider, Physician Liaison to the NASA Human Research Programme and Dr John Allen, Audiologist and member of the Human Exploration. As part of the visit Dr JD Polk gave a sold-out .

Clinical

Professor Sinclair completed her Certificate of Specialist Training in Neurology in 2013 and established and previously led the Complex Headache Service at University Hospital Birmingham. She is a keen advocate and supporter of the multi-disciplinary care approach for Idiopathic intracranial hypertension and traumatic brain injury run at University Hospital Birmingham. She has a particular interest in traumatic brain injury and post-traumatic headache. She is passionate about driving excellence in clinical care and moving knowledge from research to improved patient outcomes.

Teaching Programmes

• MBChB
• BMedSci

Professor Sinclair's work is supported by a number of academic grants and collaborations with industry.

Defining new treatment and headache mechanisms in raised intracranial pressure

Through a , Professor Sinclair is running a 5-year programme defining new treatment and headache mechanisms in raised intracranial pressure. A previous small clinical trial and shown . In this research program she will be evaluating the efficacy of a GLP-1 receptor agonist to treat Idiopathic Intracranial Hypertension (IIH) through a large UK randomised control trial. Mechanistic work will comprise human physiology studies with complimentary in vivo studies. 

Establishing the optimal surgical intervention to preserve vision in IIH

This UK multi-centre randomised control trial funded by the NIHR HTA for six years will evaluate the effectiveness and cost effectiveness of dual venous sinus stenting compared to cerebrospinal fluid shunting to prevent visual loss in fulminant IIH. The trial is called IIH: Intervention and is a UK wide multicentre-trial.

Defining the metabolic contributors to intracranial pressure regulation

Utilising in vivo models with intracranial pressure monitoring, the group is exploring mechanisms that regulate intracranial pressure. 

Establishing accurate biomarkers for mild traumatic brain injury

Funded by the US Department of Defence and UK Ministry of Defence (total funds > £15.5M)  in collaboration with the Royal Centre of Defence Medicine, this study is seeking to identify accurate reproducible biomarkers in mild traumatic brain injury (mTBI) that will predict the most common and disabling consequences of mTBI: primarily persistent post-traumatic headache, as well as cognitive dysfunction, depression, PTSD, dizziness and return to work. This will be achieved through an interdisciplinary harmonised research programme consisting of detailed clinical phenotyping of acute mTBI patients coupled with state-of-the-art multimodal biomarker evaluation (brain imaging, fluid biomarkers, steroid hormones, visual, vestibular, cerebral physiology and EEG biomarkers) in both military and civilian patients. The study will run over 8 years and is called mTBI Predict.

Investigate the optimal method of therapeutic weight management in IIH

Through a five year research programme funded by the NIHR, a randomised control trial (IIH:WT) has previously evaluated the optimal method of treating IIH through weight loss by comparing a , . The programme additionally seeks to identify the relationship between weight and . As well as by which .

Laboratory science to evaluate mechanism and novel therapeutics in headache and traumatic brain injury

The Translational Brain Science Preclinical Laboratory Team spans from  in vivo to in vitro laboratory research and  aims to understand and treat neurological conditions associated with headache, raised intracranial pressure and traumatic brain injury.

Membership of professional bodies

• (since 2018)
•  (MRCP) UK (since 2003)

Public engagement

• Previously Patron of charity (producing patient information leaflets, information videos and dissemination of clinically relevant information research through the annual patient conference). 

Patents and commercialisation

• Patent: Inventor for the use of GLP-1 agonists in intracranial pressure, no: 1415598 (filed 2014 US, EU, ROW: granted 2019 ROW 2020 EU & US)
• Orphan Drug designation: European Medicine Agency and FDA 2016.
• Spin out company: , Founder, Previous Executive Director and Chief Scientific Officer (formed 2018 and listed on the Australian Stock exchange following capital raises of AUS $38).